MX2018009247A - Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. - Google Patents
Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.Info
- Publication number
- MX2018009247A MX2018009247A MX2018009247A MX2018009247A MX2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A MX 2018009247 A MX2018009247 A MX 2018009247A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapies
- histone deacetylase
- enhancing
- deacetylase inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288121P | 2016-01-28 | 2016-01-28 | |
| PCT/US2017/015389 WO2017132536A1 (en) | 2016-01-28 | 2017-01-27 | Use of histone deacetylase inhibitors for enhancing immunotherapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009247A true MX2018009247A (es) | 2019-03-11 |
Family
ID=58010402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009247A MX2018009247A (es) | 2016-01-28 | 2017-01-27 | Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10813919B2 (https=) |
| EP (1) | EP3407913A1 (https=) |
| JP (1) | JP2019503386A (https=) |
| KR (1) | KR20180104122A (https=) |
| CN (1) | CN108883179A (https=) |
| AU (1) | AU2017211383A1 (https=) |
| BR (1) | BR112018015291A2 (https=) |
| CA (1) | CA3013047A1 (https=) |
| IL (1) | IL260765A (https=) |
| MX (1) | MX2018009247A (https=) |
| RU (1) | RU2018130831A (https=) |
| WO (1) | WO2017132536A1 (https=) |
| ZA (1) | ZA201805066B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| CA3066053A1 (en) | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
| WO2019140296A1 (en) * | 2018-01-12 | 2019-07-18 | Viracta Therapeutics, Inc. | Epigenetic modifiers for use in cellular immunotherapy |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| CN112569360A (zh) * | 2019-09-30 | 2021-03-30 | 中国医学科学院药物研究所 | 一种基于阻断pd-1/pd-l1的抗肿瘤药物组合物及其应用 |
| CA3227993A1 (en) | 2021-08-11 | 2023-02-16 | OncoHost Ltd. | Predicting patient response |
| WO2024231293A1 (en) * | 2023-05-05 | 2024-11-14 | Euro-Celtique S.A. | Combinations for treating cancer |
| US20240382463A1 (en) * | 2023-05-18 | 2024-11-21 | Avstera Therapeutics Corp. | Composition Comprising HDAC Inhibitor and Immune Checkpoin Inhibitor and Methods For Using the Same |
| US12553903B2 (en) | 2023-06-01 | 2026-02-17 | Cg Pharmaceuticals, Inc | Ivaltinostat combination therapy for treating pancreatic cancer |
| WO2025155922A1 (en) * | 2024-01-19 | 2025-07-24 | The Trustees Of Indiana University | Hdac3 inhibitors to treat arrhythmogenic cardiomyopathy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| US9987258B2 (en) * | 2014-04-06 | 2018-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase as a modulator of PDL1 expression and activity |
| JP2018508593A (ja) * | 2015-03-20 | 2018-03-29 | シンダックス ファーマシューティカルズ，インコーポレイティド | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ |
| US20180250320A1 (en) | 2015-08-26 | 2018-09-06 | The Johns Hopkins University | Compositions and methods for treating solid tumors |
| AU2016318136B2 (en) * | 2015-09-02 | 2022-10-20 | Syndax Pharmaceuticals, Inc. | Selection of patients for combination therapy |
-
2017
- 2017-01-27 RU RU2018130831A patent/RU2018130831A/ru not_active Application Discontinuation
- 2017-01-27 BR BR112018015291A patent/BR112018015291A2/pt not_active IP Right Cessation
- 2017-01-27 AU AU2017211383A patent/AU2017211383A1/en not_active Abandoned
- 2017-01-27 KR KR1020187024674A patent/KR20180104122A/ko not_active Withdrawn
- 2017-01-27 EP EP17704370.0A patent/EP3407913A1/en not_active Withdrawn
- 2017-01-27 WO PCT/US2017/015389 patent/WO2017132536A1/en not_active Ceased
- 2017-01-27 US US16/072,659 patent/US10813919B2/en active Active
- 2017-01-27 CN CN201780020460.2A patent/CN108883179A/zh active Pending
- 2017-01-27 JP JP2018539087A patent/JP2019503386A/ja active Pending
- 2017-01-27 MX MX2018009247A patent/MX2018009247A/es unknown
- 2017-01-27 CA CA3013047A patent/CA3013047A1/en not_active Abandoned
-
2018
- 2018-07-24 IL IL260765A patent/IL260765A/en unknown
- 2018-07-27 ZA ZA2018/05066A patent/ZA201805066B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190030011A1 (en) | 2019-01-31 |
| WO2017132536A1 (en) | 2017-08-03 |
| JP2019503386A (ja) | 2019-02-07 |
| EP3407913A1 (en) | 2018-12-05 |
| CA3013047A1 (en) | 2017-08-03 |
| RU2018130831A3 (https=) | 2020-04-23 |
| BR112018015291A2 (pt) | 2018-12-18 |
| KR20180104122A (ko) | 2018-09-19 |
| CN108883179A (zh) | 2018-11-23 |
| IL260765A (en) | 2018-10-31 |
| ZA201805066B (en) | 2019-05-29 |
| US10813919B2 (en) | 2020-10-27 |
| AU2017211383A1 (en) | 2018-08-16 |
| RU2018130831A (ru) | 2020-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009247A (es) | Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias. | |
| PH12022550469A1 (en) | Kras g12d inhibitors | |
| CY1123676T1 (el) | Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων | |
| ZA202007007B (en) | Mcl-1 inhibitors | |
| WO2019112899A8 (en) | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS | |
| MY200356A (en) | Kras g12c inhibitors | |
| PH12019501396A1 (en) | Compositions and methods for inhibiting arginase activity | |
| MX2024008062A (es) | Proteinas de enlace a mesotelina. | |
| MX387326B (es) | Preparados combinados para el tratamiento contra el cancer o infecciones | |
| MX382624B (es) | Compuestos farmacéuticos. | |
| MX2021006194A (es) | Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc. | |
| MX395342B (es) | Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2. | |
| EA201500394A1 (ru) | Ингибиторы деметилаз гистонов | |
| PH12019550027A1 (en) | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer | |
| EA201790968A1 (ru) | Опосредуемая пептидом доставка направляемой рнк эндонуклеазы в клетки | |
| MX371108B (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| EP4527922A3 (en) | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof | |
| EA201400772A1 (ru) | Варианты полипептидов ph20, композиции на их основе и их применение | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| EA201791933A1 (ru) | Ингибирование активности olig2 | |
| PH12021551475A1 (en) | Heterodimeric proteins for modulating gamma delta t cells | |
| MY203626A (en) | Compositions and methods for inhibiting the biological activity of soluble biomolecules | |
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| WO2019100079A8 (en) | Compositions for improving car-t cell functionality and use thereof |